1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Human Virome Program (HVP) is sponsored by National Institutes of Health (NIH) Common Fund. The Human Virome Program aims to describe the 'healthy' virome – the collection of viruses that normally reside inside the human body without evidence of disease – and to improve understanding of its role in shaping human health.
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health (NIH) Common Fund” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Human Virome Program | NIH Common Fund What is the Human Virome Program? Watch the Video What is the NIH Common Fund Human Virome Program? This video provides an overview of the NIH Common Fund Human Virome Program and its goals.
The overall goal of the NIH Human Virome Program (HVP) is to describe the “healthy” virome – the collection of viruses that normally reside inside the human body without evidence of disease – and to improve our understanding of the role it plays in shaping human health.
Viruses are the most abundant and diverse biological entities on earth, and while much of the existing research on viruses has focused on a small number that cause illness, far less attention has been given to the many other viruses that coexist with us and that are not associated with a known or sudden disease.
Despite recent technological advances, it has been challenging to explore these largely understudied viruses that make up this “healthy” human virome. To address this gap, the Human Virome Program will describe the members of the human virome, and develop tools and methods to extensively study the virome in groups of individuals without signs of overt disease and across multiple stages of life.
Investigating the human microbiome – the collection of microbes like bacteria that live in and on us – profoundly changed our understanding of the role our microbe partners play in keeping us healthy. This program has the potential to do the same for viruses. The Human Virome program consists of four initiatives that will work synergistically to achieve the goals of the program.
These initiatives will: Describe and catalog the human virome in many different groups of people covering a broad span of ages. Develop innovative tools, models, and methods to identify and describe the human virome. Study interactions between the human body and the human virome.
Coordinate data generated by the program and make it accessible to other researchers. The program will help us understand how we acquire our virome and its roles in human development, the immune system, and supporting overall health.
One day, contributions from the program may also include new biomarkers for identifying emergent or chronic diseases and conditions, the development of potential therapies, as well as the discovery and identification of potential viruses that may play a central role in keeping us healthy.
The NIH approves the Human Virome Program Summary Report of the Human Virome Planning Workshop Human Virome Program Proposal September 8, 2022 – DPCPSI Council of Councils slides September 8, 2022 – DPCPSI Council of Councils Human Virome Proposal Presentation [at time 2:15:26] This page last reviewed on
According to the current listing, eligibility includes: Researchers and institutions involved in biomedical research. Confirm the full requirements in the official notice before applying.
Human Virome Program (HVP) is funded by National Institutes of Health (NIH) Common Fund. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NIH Director's Transformative Research Award for Individual and Group Science (R01 Clinical Trial Optional) (RFA-RM-27-003) is sponsored by National Institutes of Health (NIH) Common Fund. This award supports individual scientists or groups proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop trans…
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) Common Fund. This opportunity focuses on developing and testing standard processes to support responsible AI use, data management, and regulatory readiness within the context of the PRIMED-AI program, which aims to integrate clinical imaging with other health data for AI-powered clinical decision support tools.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
Avoid common NIH grant proposal mistakes including vague specific aims, weak methodology, and poor budget justification that lead to rejection.
Read articleOMB's proposed rewrite of 2 CFR Part 200 would bar political appointees from deferring to peer reviewers and require senior-appointee sign-off on every discretionary grant. NIH new awards are already down about 34% in 2026. Here is what the merit-review changes actually say, how 'Gold Standard Science' becomes a scoring lever, why R1 universities are being written out of some solicitations, and what principal investigators and research offices should do before October 1.
Read articleNIH's June 1 omnibus reset added Direct-to-Phase II to the STTR program for the first time. The change compresses university spinouts' funding timeline from three years to fifteen months, but the 30% research-institution subaward, feasibility-evidence rules, and IP licensing mechanics are not yet sorted at most universities.
Read article